Sanofi, Teva Collaborate on Inflammatory Bowel Disease Drug
October 04 2023 - 1:57AM
Dow Jones News
By Pierre Bertrand
Sanofi said that it has entered into an exclusive collaboration
with Teva Pharmaceuticals for the development of a novel therapy to
treat ulcerative colitis and Crohn's disease.
The drug, TEV'574, will be co-developed and co-commercialized by
the two companies. It is currently in Phase 2b clinical trials,
according to a joint statement published on Wednesday.
As part of the agreement, the Teva Pharmaceutical Industries
subsidiary will receive an upfront payment of 469 million euros
($490.8 million) and up to EUR940 million ($983.8 million) in
development and launch milestones.
Teva will lead commercialization of the drug in Europe, Israel
and in other countries, while Sanofi will focus on North America,
Japan, other parts of Asia as well as in the rest of the world, the
companies said.
The transaction will be effective after customary closing
conditions are met. Initial program results are expected available
next year.
Sanofi will lead the development of the phase 3 program, the
companies said.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
October 04, 2023 01:42 ET (05:42 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024